Galgt2 gene therapy (Sarepta)

N/A

Report date: 2024/12/20 17:20:22

Base Information

Drug NameGalgt2 gene therapy (Sarepta)
Drug Alias NameGalgt2 gene therapyrAAVrh74.MCK.GALGT2GalNAc tranferase gene therapiesGALGT2rAAVrh 74 MCK GALGT2
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh74 vector
Mechanisms of ActionBeta-1,4 N-acetylgalactosaminyltransferase 2 gene transference
TargetsBeta-1,4 N-acetylgalactosaminyltransferase 2
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncNationwide Children'S Hospital
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A